The pursuit of outperformance leads many investors to carefully choose individual stocks. Picking the right ones can be a game-changer for growing your wealth.
The price of Beam Therapeutics Inc (NASDAQ: BEAM) closed at $34.09 in the last session, up 1.79% from day before closing price of $33.49. In other words, the price has increased by $1.79 from its previous closing price. On the day, 1.58 million shares were traded.
Ratios:
We take a closer look at BEAM’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 5.69 and its Current Ratio is at 5.69. In the meantime, Its Debt-to-Equity ratio is 0.20 whereas as Long-Term Debt/Eq ratio is at 0.19.
On November 06, 2024, Leerink Partners Upgraded its rating to Outperform which previously was Market Perform and also upped its target price recommendation from $27 to $39.
Insider Transactions:
An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Feb 14 ’25 when Bellon Christine sold 10,000 shares for $34.00 per share. The transaction valued at 340,000 led to the insider holds 102,968 shares of the business.
CHRISTINE BELLON bought 10,000 shares of BEAM for $340,000 on Feb 14 ’25. On Jan 30 ’25, another insider, Evans John M., who serves as the CEO of the company, sold 30,000 shares for $26.75 each. As a result, the insider received 802,484 and left with 908,659 shares of the company.
Valuation Measures:
For the stock, the TTM Price-to-Sale (P/S) ratio is 8.07 while its Price-to-Book (P/B) ratio in mrq is 3.56.
Stock Price History:
Over the past 52 weeks, BEAM has reached a high of $49.50, while it has fallen to a 52-week low of $20.84. The 50-Day Moving Average of the stock is 26.13%, while the 200-Day Moving Average is calculated to be 33.75%.
Shares Statistics:
A total of 82.56M shares are outstanding, with a floating share count of 72.89M. Insiders hold about 11.98% of the company’s shares, while institutions hold 84.26% stake in the company.
